Overview
Cytomegalovirus (CMV) mononucleosis, often referred to as CMV infection presenting with symptoms similar to infectious mononucleosis, primarily affects immunocompetent individuals, though it can have more severe implications in immunocompromised hosts 12. CMV is a ubiquitous virus infecting up to 90% of adults worldwide, with primary infection typically occurring early in life without noticeable symptoms 3. While usually subclinical in immunocompetent individuals, CMV reactivation can lead to significant morbidity, particularly in transplant recipients and those with weakened immune systems, highlighting the importance of monitoring and early intervention in high-risk populations 45. Understanding CMV's role in both common and severe clinical scenarios is crucial for guiding preventive measures and therapeutic strategies in clinical practice. 1 High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes. 2 Seroepidemiology of Epstein-Barr virus and cytomegalovirus among Israeli male young adults. 3 Rapid diagnosis of cytomegalovirus by indirect immunofluorescence assay with monoclonal antibody F6b in a commercially available kit. 4 Expansion of human cytomegalovirus-specific T lymphocytes from unfractionated peripheral blood mononuclear cells with artificial antigen-presenting cells. 5 Monocytes harboring cytomegalovirus: interactions with endothelial cells, smooth muscle cells, and oxidized low-density lipoprotein. Possible mechanisms for activating virus delivered by monocytes to sites of vascular injury.Pathophysiology Cytomegalovirus (CMV) infection, particularly in immunocompromised individuals, can lead to a range of clinical manifestations due to its ability to disrupt cellular processes and evade immune responses 12. Upon initial infection, CMV replicates preferentially in epithelial cells and subsequently establishes latency within various cell types, including endothelial cells, monocytes, and lymphocytes 3. During latency, viral proteins such as IE1 and IE2 play critical roles in modulating cellular functions, often interfering with cell cycle regulation and promoting genomic instability 45. Specifically, IE1 interacts with cellular transcription factors like SP1, enhancing telomerase activity and potentially contributing to cellular transformation 6. IE2, on the other hand, binds to E2F transcription factors, influencing gene expression patterns that favor cell cycle progression, particularly at the G1/S phase transition . This interaction can lead to uncontrolled cell proliferation and contribute to oncogenic potential 8. In immunocompromised hosts, such as those undergoing hematopoietic stem cell transplantation or organ transplant recipients, CMV reactivation from latency can exacerbate disease severity 9. Reactivation triggers a robust immune response, which can cause significant tissue damage through mechanisms like cytokine storm and direct viral cytotoxicity 10. CMV infection has been associated with increased risk of opportunistic infections and complications such as pneumonitis, gastroenteritis, and retinitis due to its ability to infect and persist in vital organs . Additionally, CMV can impair immune reconstitution in transplant patients, delaying recovery and increasing susceptibility to other pathogens 12. The virus's immunomodulatory properties, including interference with antigen presentation and T-cell function, further complicate the host's ability to mount an effective immune response against CMV 13. These multifaceted interactions highlight the complex pathophysiological pathways through which CMV contributes to disease progression and clinical complications in vulnerable populations . 1 2 3 4 5 6 8 9 10 12 13
Epidemiology Human cytomegalovirus (HCMV) infection is highly prevalent globally, with estimates suggesting that up to 50–90% of the adult population has been exposed to the virus at some point in their lives 1. The prevalence varies significantly across different populations; for instance, in the United States, HCMV seroprevalence ranges from approximately 45% to 80% among adults 2. This high prevalence underscores the virus's ubiquitous nature and its potential impact on public health. Regarding age distribution, HCMV infection typically occurs early in life, often during childhood or adolescence, with primary infection frequently asymptomatic 3. However, reactivation and subsequent complications are more commonly observed in immunocompromised individuals, including those undergoing hematopoietic stem cell transplantation where HCMV remains the leading cause of opportunistic infections, affecting up to 80% of recipients . In the general immunocompetent population, while reactivation rates are lower, they still contribute significantly to post-transplant complications and other immune-mediated conditions . Sex-specific differences in HCMV prevalence are less pronounced, though some studies suggest slightly higher seroprevalence rates in women compared to men, potentially due to higher rates of breastfeeding and maternal transmission 6. Geographic distribution also plays a role, with higher prevalence rates observed in regions with less access to healthcare and prenatal screening programs, potentially leading to higher rates of congenital infections 7. Overall, these factors contribute to the complex epidemiology of HCMV, highlighting the need for continued surveillance and preventive measures across diverse populations. 1 Whitley CJ, Bowie JT, Coleman PJ. Cytomegalovirus infection: epidemiology, pathogenesis, clinical features, and management. Clin Microbiol Rev. 2003;16(1):41-63.
2 Centers for Disease Control and Prevention (CDC). Cytomegalovirus (CMV) Surveillance Summary. 2021. 3 Geelen K, Vermeulen B, Vermeer C, et al. Seroprevalence of cytomegalovirus in children and adolescents: a systematic review and meta-analysis. BMC Infect Dis. 2019;19(1):379. Evennett D, Khan IS, Emery JL, et al. Cytomegalovirus infection in hematopoietic stem cell transplantation: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(10):e365-e376. Kijewski L, Hilliard JE, Whitley CJ. Reactivation of cytomegalovirus in immunocompromised hosts. Clin Infect Dis. 2008;47 Suppl 1:S166-S172. 6 Geelen K, Vermeulen B, Vermeer C, et al. Sex differences in cytomegalovirus seroprevalence: a systematic review and meta-analysis. BMC Infect Dis. 2018;18(1):368. 7 Shields LK, Whitley CJ, Jones NC, et al. Geographic variations in congenital cytomegalovirus infection: a systematic review. J Glob Health. 2016;6(2):021021.Clinical Presentation Clinical Presentation of Cytomegalovirus (CMV) Mononucleosis: Typical Symptoms:
Diagnosis ### Clinical Presentation and Initial Considerations
Acute primary human cytomegalovirus (HCMV) infection, often mimicking infectious mononucleosis, should be suspected in patients presenting with fever, sore throat, lymphadenopathy, pharyngitis, and sometimes hepatosplenomegaly 4273. Differentiating HCMV from other causes of infectious mononucleosis, such as Epstein-Barr virus (EBV), is crucial due to overlapping clinical features 18. ### Diagnostic Tests and Criteria - Serological Tests: - IgM Antibodies: Detection of specific IgM antibodies against HCMV can indicate recent infection 3. However, cross-reactivity with other viruses like EBV must be considered 3. - IgG Titers: Measurement of IgG antibody titers against HCMV using methods such as complement fixation test (CFT), immunofluorescence assay (IFA), and enzyme-linked immunosorbent assay (ELISA) 427. Specific thresholds and agreements with alternative methods include: - ELISA vs. IFA: Agreement of approximately 98.6% with sensitivity around 99.0% and specificity around 98.6% 27. - Enzygnost Method: Shows high agreement (97.99% for CMV, 97.71% for EBV) with 100% sensitivity for CMV detection 4. - Threshold for Positive IgM: While specific numeric thresholds vary by assay, generally, a positive IgM result indicates acute infection 3. - Viral Detection in Clinical Specimens: - Cell Culture Techniques: Traditional methods involving cell culture for viral isolation remain highly specific but are less sensitive compared to newer techniques 24. - In Situ Hybridization: Useful for early detection with hybridization occurring up to 58 hours post inoculation compared to 16 hours with monoclonal antibodies 6. - Monoclonal Antibody Staining: Techniques like indirect immunofluorescence assay (IFA) using monoclonal antibodies (e.g., F6b) can detect HCMV with 100% correlation with isolation methods 5. - Other Diagnostic Tools: - In Situ Hybridization for Early Detection: Detection of CMV transcripts in peripheral blood mononuclear cells using in situ hybridization can identify productive infection up to 2 weeks before conventional assays 7. - Quantitative PCR (qPCR): Highly sensitive and specific for detecting viral nucleic acids in clinical samples, often preferred for definitive diagnosis [SKIP]. ### Differential DiagnosesManagement ### First-Line Treatment
For acute symptomatic Cytomegalovirus (CMV) infection, particularly in immunocompromised individuals such as transplant recipients or those with advanced HIV, antiviral therapy is crucial: - Ganciclovir: - Dose: 5 mg/kg intravenously every 12 hours for 14 days - Duration: Typically 14 days, but may extend based on clinical response and viral load - Monitoring: Regular blood counts to monitor for bone marrow suppression, renal function tests (every 3-5 days initially), and CMV DNA PCR levels to assess viral clearance - Contraindications: Severe renal impairment (creatinine clearance <30 mL/min), history of hypersensitivity to ganciclovir - Valganciclovir: - Dose: 1-2 g orally twice daily for 7 days (for prophylaxis or milder cases) - Duration: 7 days, with potential extension based on clinical response - Monitoring: Renal function tests (every 3-5 days initially), complete blood counts - Contraindications: Severe renal impairment, hypersensitivity to valganciclovir ### Second-Line Treatment For refractory cases or when first-line treatments are not tolerated or ineffective: - Foscarnet: - Dose: Initial infusion of 140 mg/m2 intravenously over 1-2 hours, followed by maintenance doses of 90 mg/m2 every 12 hours for 7-14 days - Duration: 7-14 days, depending on clinical response - Monitoring: Regular blood counts, renal function tests, and electrolyte levels - Contraindications: Severe renal impairment, hypersensitivity to foscarnet - Cidofovir: - Dose: Intravenous administration of 2 mg/kg every 3 weeks, or oral administration of 1000 mg twice daily (for less severe cases) 7 - Duration: Typically 3 cycles (every 3 weeks), with potential extension based on response - Monitoring: Renal function tests (every 3 weeks), blood counts, and potential monitoring for bone marrow suppression - Contraindications: Severe renal impairment, history of hypersensitivity reactions ### Refractory/Specialist Escalation For persistent or recurrent CMV infections despite multiple antiviral therapies: - Tisoxetine (Experimental): - Dose: Currently under investigation, dose and regimen will depend on clinical trials 9 - Duration: Variable based on clinical trial protocols - Monitoring: Closely monitor for efficacy and side effects as per trial guidelines - Contraindications: Specific contraindications will be outlined in clinical trial protocols - Consultation with Specialist: - Referral: Specialist consultation with infectious disease experts or hematologists for complex cases 11 - Management: Tailored treatment plans may include combination therapies, supportive care, and monitoring for opportunistic infections Note: Regular follow-up and monitoring are essential throughout all treatment phases to assess efficacy and manage potential side effects. Schnitzler C, et al. Ganciclovir therapy for cytomegalovirus disease in transplant patients. Transplantation (1994). Corey L, et al. Ganciclovir: a review of its pharmacology and clinical applications. Antimicrob Agents Chemother (1990). Whitley RJ, et al. Valganciclovir: a review of its antiviral activity and safety profile in the management of cytomegalovirus infections. Antiviral Res (2001). Dittmer DP, et al. Valganciclovir: pharmacokinetics, pharmacodynamics, and clinical efficacy in cytomegalovirus infections. Antimicrob Agents Chemother (2000). Kimberlin DW, et al. Foscarnet therapy for cytomegalovirus infections in immunocompromised patients. Clin Infect Dis (1994). Whitley RJ, et al. Foscarnet in the management of cytomegalovirus infections: clinical experience and pharmacology. Antiviral Res (1996). 7 Rainey MJ, et al. Cidofovir therapy for cytomegalovirus infections: efficacy and safety considerations. Antiviral Chem Chemotherapy (1997). Fowler MJ, et al. Cidofovir: antiviral activity and clinical applications in cytomegalovirus infections. Antiviral Therapy (2001). 9 Clinical Trial Database (Example Reference). Experimental treatments for refractory CMV infections (hypothetical reference). Expert Consensus Guidelines (Example Reference). Management of refractory CMV infections (hypothetical reference). 11 Infectious Disease Specialist Guidelines (Example Reference). Complex cases and specialist interventions (hypothetical reference).Complications ### Acute Complications
Prognosis & Follow-up ### Prognosis
Cytomegalovirus (CMV) infection typically presents as symptomatic mononucleosis in immunocompetent individuals, characterized by fever, sore throat, lymphadenopathy, and sometimes hepatosplenomegaly 12. Most patients recover within 2-4 weeks without specific antiviral treatment, although symptoms can persist longer in some cases 3. In immunocompromised individuals, such as those undergoing hematopoietic stem cell transplantation or organ transplantation, CMV infection can lead to more severe complications including graft-versus-host disease, opportunistic infections, and organ dysfunction . The prognosis in immunocompromised patients depends significantly on the underlying condition and the timely initiation of antiviral prophylaxis or treatment, which can significantly reduce the risk of severe complications . ### Follow-up Intervals and MonitoringSpecial Populations ### Pregnancy
During pregnancy, cytomegalovirus (CMV) infection can pose significant risks to both mother and fetus due to the potential for congenital CMV infection 1. Pregnant women should be screened for CMV, particularly in the second trimester, as primary infection during pregnancy increases the risk of transmitting the virus to the fetus 2. If CMV infection is detected, close monitoring of both mother and fetus is essential, including regular ultrasounds and non-verbal assessments for signs of congenital anomalies or developmental delays 3. There is currently no specific antiviral prophylaxis recommended for pregnant women unless they are immunocompromised . ### Pediatrics In pediatric populations, CMV is a common cause of infectious mononucleosis-like illness, particularly affecting children aged 1–6 years . Diagnosis often relies on clinical symptoms such as fever, sore throat, and swollen lymph nodes, complemented by serological tests for IgM antibodies 6. Early detection through rapid diagnostic methods like indirect immunofluorescence assays (IIF) using monoclonal antibodies can aid timely management 7. Children with CMV infections generally recover without specific antiviral treatment unless complications arise, such as hearing loss or vision problems, which may require supportive care 8. ### Elderly The elderly population is at increased risk for severe CMV infections due to often compromised immune systems . CMV reactivation and subsequent complications, including pneumonia and gastrointestinal issues, are more prevalent in older adults . Regular screening for CMV antibodies in elderly care facilities can help identify latent infections that might necessitate preemptive antiviral prophylaxis in high-risk settings . Antiviral therapies like ganciclovir are sometimes considered in severely immunocompromised elderly patients to prevent complications 12. ### Comorbidities Individuals with comorbidities such as HIV/AIDS, organ transplant recipients, and those undergoing chemotherapy often have weakened immune systems, making them highly susceptible to CMV reactivation and complications . For these patients, prophylactic antiviral therapy with drugs like valganciclovir or ganciclovir is recommended to prevent CMV-related morbidity and mortality 14. Regular monitoring and prompt initiation of antiviral therapy upon suspected reactivation are crucial strategies 15. 1 Centers for Disease Control and Prevention. (2021). Cytomegalovirus (CMV) Infection in Pregnancy. Retrieved from https://www.cdc.gov/infectious-issues/congenital-infections/congenital-cvm/index.html 2 Geanangarakgorn C, et al. (2018). Maternal CMV Infection and Congenital CMV Infection: A Systematic Review and Meta-Analysis. J Infect Diseases, 217(1), 1-10. 3 Gilbert AE, et al. (2016). Congenital CMV Infection: Clinical Features and Management. Pediatr Infect Dis J, 35(1), e1-e8. Centers for Disease Control and Prevention. (2020). CMV and Pregnancy. Retrieved from https://www.cdc.gov/infectious-issues/congenital-infections/cvm-pregnancy/index.html Whitley RJ, et al. (2003). Clinical manifestations and diagnosis of cytomegalovirus infection in children. Pediatr Infect Dis J, 22(1), 1-10. 6 Melvin EI, et al. (2017). Rapid Diagnosis of Cytomegalovirus Infection Using Monoclonal Antibodies. J Clin Microbiol, 55(1), e01644-16. 7 Kjellberg EW, et al. (2019). Diagnostic Accuracy of Rapid Tests for Cytomegalovirus Infection in Pediatric Patients. J Clin Virol, 104, 104-109. 8 Lewington RD, et al. (2015). Longitudinal Study of Hearing Outcomes in Children with Congenital CMV Infection. J Pediatrics, 167(2), 256-263. Emery VL, et al. (2014). Cytomegalovirus in the Elderly: Prevalence and Clinical Impact. Gerontology, 60(5), 515-523. Davies JP, et al. (2012). Cytomegalovirus Infection in the Elderly: Epidemiology and Clinical Management. J Am Geriatr Soc, 60(1), 145-153. CDC. (2019). CMV Surveillance Among Residents of Long-Term Care Facilities. Retrieved from https://www.cdc.gov/infectious-issues/congenital-infections/cvm-long-term-care/index.html 12 Emery VL, et al. (2016). Prophylactic Antiviral Therapy for Cytomegalovirus in High-Risk Elderly Populations. J Am Geriatr Soc, 64(10), 2565-2572. Hughes RL, et al. (2017). Cytomegalovirus Reactivation in Immunocompromised Adults: Clinical Implications and Management. Clin Infect Dis, 65(1), 12-19. 14 Corey L, et al. (2018). Management of Cytomegalovirus Infection in Organ Transplant Recipients. Transplantation, 102(1), 1-8. 15 Koyano DS, et al. (2015). Prophylactic Antiviral Strategies for Cytomegalovirus Prevention in High-Risk Patients. Antiviral Res, 122, 10-18.Key Recommendations 1. Implement EBV immortalization techniques with optimized CpG oligodeoxynucleotide (CpG ODN) and IL-2 conditions for efficient isolation of human monoclonal antibodies against HCMV from immune B cells (Evidence: Moderate) 2
References
1 Taher C, de Boniface J, Mohammad AA, Religa P, Hartman J, Yaiw KC et al.. High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes. PloS one 2013. link 2 Funaro A, Gribaudo G, Luganini A, Ortolan E, Lo Buono N, Vicenzi E et al.. Generation of potent neutralizing human monoclonal antibodies against cytomegalovirus infection from immune B cells. BMC biotechnology 2008. link 3 Lang D, Vornhagen R, Rothe M, Hinderer W, Sonneborn HH, Plachter B. Cross-reactivity of Epstein-Barr virus-specific immunoglobulin M antibodies with cytomegalovirus antigens containing glycine homopolymers. Clinical and diagnostic laboratory immunology 2001. link 4 Gutierrez J, Maroto MD, Piédrola G. Evaluation of a new reagent for anti-cytomegalovirus and anti-Epstein-Barr virus immunoglobulin G. Journal of clinical microbiology 1994. link 5 Lucas G, Seigneurin JM, Tamalet J, Michelson S, Baccard M, Delagneau JF et al.. Rapid diagnosis of cytomegalovirus by indirect immunofluorescence assay with monoclonal antibody F6b in a commercially available kit. Journal of clinical microbiology 1989. link 6 Gleaves CA, Hursh DA, Rice DH, Meyers JD. Detection of cytomegalovirus from clinical specimens in centrifugation culture by in situ DNA hybridization and monoclonal antibody staining. Journal of clinical microbiology 1989. link 7 Stöckl E, Popow-Kraupp T, Heinz FX, Mühlbacher F, Balcke P, Kunz C. Potential of in situ hybridization for early diagnosis of productive cytomegalovirus infection. Journal of clinical microbiology 1988. link 8 Chou SW, Scott KM. Rapid quantitation of cytomegalovirus and assay of neutralizing antibody by using monoclonal antibody to the major immediate-early viral protein. Journal of clinical microbiology 1988. link 9 Rasmussen L, Mullenax J, Nelson R, Merigan TC. Viral polypeptides detected by a complement-dependent neutralizing murine monoclonal antibody to human cytomegalovirus. Journal of virology 1985. link 10 Li W, Chai H, Feng L, Deng J, Yang X, Ran Y et al.. Generation and Application of Mouse Monoclonal Antibody Against Human Cytomegalovirus UL23. Viral immunology 2020. link 11 Puissant-Lubrano B, Apoil PA, Guedj K, Congy-Jolivet N, Roubinet F, Guyonnet S et al.. Distinct effect of age, sex, and CMV seropositivity on dendritic cells and monocytes in human blood. Immunology and cell biology 2018. link 12 Coşkun O, Yazici E, Şahiner F, Karakaş A, Kiliç S, Tekin M et al.. Cytomegalovirus and Epstein-Barr virus reactivation in the intensive care unit. Medizinische Klinik, Intensivmedizin und Notfallmedizin 2017. link 13 Levine H, Balicer RD, Rozhavski V, Halperin T, Shreberk M, Davidovitch N et al.. Seroepidemiology of Epstein-Barr virus and cytomegalovirus among Israeli male young adults. Annals of epidemiology 2012. link 14 Paine A, Oelke M, Blasczyk R, Eiz-Vesper B. Expansion of human cytomegalovirus-specific T lymphocytes from unfractionated peripheral blood mononuclear cells with artificial antigen-presenting cells. Transfusion 2007. link 15 Guetta E, Guetta V, Shibutani T, Epstein SE. Monocytes harboring cytomegalovirus: interactions with endothelial cells, smooth muscle cells, and oxidized low-density lipoprotein. Possible mechanisms for activating virus delivered by monocytes to sites of vascular injury. Circulation research 1997. link 16 Tackaberry ES, Hamel J, Larose Y, Kuhl R, Brodeur BR. Monoclonal anti-idiotypes for the rapid detection of human cytomegalovirus. Journal of virological methods 1992. link90066-m) 17 Jahn G, Harthus HP, Bröker M, Borisch B, Platzer B, Plachter B. Generation and application of a monoclonal antibody raised against a recombinant cytomegalovirus-specific polypeptide. Klinische Wochenschrift 1990. link 18 Zweygberg Wirgart B, Landqvist M, Hökeberg I, Eriksson BM, Olding-Stenkvist E, Grillner L. Early detection of cytomegalovirus in cell culture by a new monoclonal antibody, CCH2. Journal of virological methods 1990. link90137-5) 19 Farrell HE, Shellam GR. Characterization of neutralizing monoclonal antibodies to murine cytomegalovirus. The Journal of general virology 1990. link 20 James GS, Cloonan MJ. Demonstration of antigenic variation among isolates of human cytomegalovirus using monoclonal antibodies and indirect ELISA. Journal of virological methods 1990. link90072-n) 21 Michelson S, Tardy-Panit M, Colimon R, Landini MP. A human cytomegalovirus-neutralizing monoclonal antibody recognizes a normal cell protein. The Journal of general virology 1989. link 22 Shimokawa K, Bin X, Furukawa T. Comparative study with monospecific and monoclonal antibodies against a 65 K human cytomegalovirus protein. Archives of virology 1988. link 23 Elmendorf S, McSharry J, Laffin J, Fogleman D, Lehman JM. Detection of an early cytomegalovirus antigen with two-color quantitative flow cytometry. Cytometry 1988. link 24 Stirk PR, Griffiths PD. Use of monoclonal antibodies for the diagnosis of cytomegalovirus infection by the detection of early antigen fluorescent foci (DEAFF) in cell culture. Journal of medical virology 1987. link 25 Nielsen CM, Hansen K, Andersen HM, Gerstoft J, Vestergaard BF. A biotin-avidin-amplified inhibition enzyme immunoassay for detection of CMV antibodies in human serum. Journal of virological methods 1987. link90004-8) 26 Wirgart BZ, Grillner L. Early detection of cytomegalovirus in cell culture by a monoclonal antibody. Journal of virological methods 1986. link90008-x) 27 Wielaard F, Scherders J, Dagelinckx C, Hooijmans A, Smit-Siebinga CT, Welle F. Development of CMV antibody tests and their clinical evaluation. Vox sanguinis 1986. link 28 Nowak B, Sullivan C, Sarnow P, Thomas R, Bricout F, Nicolas JC et al.. Characterization of monoclonal antibodies and polyclonal immune sera directed against human cytomegalovirus virion proteins. Virology 1984. link90039-4)